Berlin

• IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after … Pending
  2025-521908-22-00 10 EGFR-mutated Non-small Cell Lung Cancer
• AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial) Pending
  2025-521929-32-01 5 First Episode Psychosis (FEP)
• Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC Pending
  2025-521971-29-00 5 Non Small Cell Lung Cancer (NSCLC)
• Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL Pending
  2025-522019-40-00 9 relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+)
• A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflamma … Pending
  2025-522076-85-00 4 Rheumatoid arthritis
• (22597) A study to learn about how safe nitroglycerin is and how it affects the body when taken along with nurandociguat in people with coro … Pending
  2025-522335-34-00 3 Chronic kidney disease
• A study to learn how safe nurandociguat is when taken with sildenafil in men with arterial hypertension. Pending
  2025-522336-14-00 3 Chronic Kidney Disease
• A Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis. Pending
  2025-522373-10-00 5 Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis
• Use of the chemotherapy FOLFIRI and cetuximab if given with treatment breaks or continuously in patients with newly diagnosed metastatic col … Pending
  2025-522377-12-00 5 metastatic colorectal cancer
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P … Pending
  2025-522471-28-00 5 psoriatic arthritis (PsA)
• LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 Pending
  2025-522475-28-00 5 Pulmonary Hypertension (PH) with Heart Failure with preserved left ven
• A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso … Pending
  2025-522586-30-00 5 Psoriatic Arthritis
• A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell L … Pending
  2025-522818-23-00 5 Small Cell Lung Cancer (SCLC)
• A Phase 2 trial to assess efficacy and safety of zasocitinib in moderate to severe hidradenitis suppurativa Pending
  2025-522831-33-00 4 Hidradenitis Suppurativa
• A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending
  2025-522855-25-00 5 Urinary Bladder Neoplasms
• An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr … Pending
  2025-522983-33-00 5 Chronic rhinosinusitis with nasal polyps
• A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden … Pending
  2025-523259-72-00 5 Hidradenitis Suppurativa (HS)
• A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending
  2025-523285-25-00 5 Relapsed or Refractory Multiple Myeloma
• Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis Pending
  2025-523400-72-00 4 Cystic fibrosis
• A Study to Access Activity and Safety with SAR445399 Compared with Placebo in Participants Aged 18 to 80 Years of Age with Non-Cystic Fibros … Pending
  2025-523403-29-00 4 Non-cystic fibrosis bronchiectasis
• Efficacy of asciminib in chronic phase CML patients with T315l mutations Pending
  2025-523491-23-00 4 Chronic Myeloid Leukemia
• Symbiotic-GI-13, A Study to Learn About the Study Medicine Called PF-08634404 as Monotherapy and Combination Therapy in Adult Participants w … Pending
  2025-523525-17-00 9 Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
• Efgartigimod as a first line attack therapy in demyelinating diseases of the central nervous system Pending
  2025-523654-13-00 10 Demyelinating diseases
• A Non-Investigational Product, Multi-Center Cohort Study to Describe Long-Term Safety and Effectiveness of Giroctocogene Fitelparvovec or Fi … Pending
  2025-523660-21-00 5 hemophilia A

Showing 73–96 of 1,792 trials